Anónimo. Mechanism target of rapamycin (mTOR): future therapeutic opportunities. Br J Clin Pharmacol 2016;82:1151-403. [Ref.ID 100930]

Anónimo. Consolidations de fracture retardées par des médicaments. Prescrire 2015;35:507-12. [Ref.ID 99440]

García E, Buenasmañanas D, Martín C, Rojas R. Neumonitis intersticial asociada a sirolimus en un paciente receptor de un trasplante de progenitores hematopoyéticos. Med Clin (Barc) 2015;145:21-3. [Ref.ID 99321]

Knoll G, Kokolo M, Mallick R, Beck A, Buenaventura C, Ducharme R, Barsoum R, Bernasconi C, Blydt-Hansen TD, Ekbergh H, Felipe CR, Firth J, Gallon L, Gelens M, Glotz D, Gossmann J, Guba M, Morsy AA, Salgo R, Scheuermann EH, Tedesco-Silva H, Vitko S, Watson C, Fergusson DA. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ 2014;349:g6679. [Ref.ID 98345]

Maeng M, Tilsted HH, Jensen LO, Krusell LR, Kaltoft A, Kelbaek H, Viladsen AB, Ravkilde J, Hansen KN, Christiansen EH, Aaroe J, Jensen JS, Kristensen SD, Botker HE, Thuesen L, Madsen M, Thayssen P, Sorensen HT, Lassen JF. Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial. Lancet 2014;383:2047-56. [Ref.ID 97702]

Stefanini GG, Windecker S. Stent performance: never too late to sort it out. Lancet 2014;383:2024-6. [Ref.ID 97701]

Anónimo. Évérolimus après transplantation hépatique. Prescrire 2013;33:730. [Ref.ID 96230]

Bailey DG, Dresser G, Arnold MO. Grapefruit-medication interactions: forbidden fruit or avoidable consequences? . Can Med Assoc J 2013;185:309-16. [Ref.ID 94799]

Stefanini GG, Homes Jr DR. Drug therapy: drug-eluting coronary-artery stents. N Engl J Med 2013;368:254-65. [Ref.ID 94789]

Pirmohamed M. Drug-grapefruit juice interactions. BMJ 2013;346:9. [Ref.ID 94758]

Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, Broeders N, del Marmol V, Chatelet V, Dompmartin A, Kessler M, Serra AL, Hofbauer GP, Pouteil-Noble C, Campistol JM, Kanitakis J, Rouox AS, Decullier E, Dantal J, TUMORAPA Study Group. Sirolimus and secondary skin cancer prevention in kidney transplantation. N Engl J Med 2012;367:329-39. [Ref.ID 93498]

Hampton T. Drug linked with diabetes. JAMA 2012;307:2247. [Ref.ID 93180]

Brophy JM. Drug-eluting stents in ST-segment elevation myocardial infarction: coment on "Drug-eluting vs bare-metal stents in primary angioplasty". Arch Intern Med 2012;172:621-2. [Ref.ID 92788]

De Luca G, Dirksen MT, Spaulding C, Kelbaek H, Schalij M, Thuesen L, van der Hoeven B, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, Díaz de la Llera LS, Pasceri V, Di Lorenzo E, Violini R, Cortese G, Suryapranata H, Stone GW, for the Drug-Eluting Stent in Primary Angioplasty (DESERT) Cooperation. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med 2012;172:611-21. [Ref.ID 92786]

Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, Kimura T, Briguori C, Sabaté M, Kim H-S, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012;379:1393-402. [Ref.ID 92725]

Ormiston JA, Webster MW. Stent thrombosis: has the firestorm been extinguished?. Lancet 2012;379:1368-9. [Ref.ID 92723]

Montastruc J-L. Médicaments déterminant HTA : du nouveau !. BIP31.fr 2012;19:19-20. [Ref.ID 92664]

Anónimo. Medicines interactions: the role of P-glycoprotein. Prescriber Update 2011;32:21-2. [Ref.ID 91143]

McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch III JP, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira Da Silva AM, Lee H-S, Krischer JP, Trapnell BC, for the National Institutes of Health Rare Lung Diseases Consortium and the MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleimyomatosis. N Engl J Med 2011;364:1595-606. [Ref.ID 90556]

Kaiser C, Pfisterer M. Drug-eluting or bare-metal stents in large coronary arteries. Author/editor response. N Engl J Med 2011;364:1180. [Ref.ID 90518]